Support us

Patient Reported Outcomes in high risk and advanced MELanoma patients (PRO-MEL) study


The primary objective of the “Patient Reported Outcomes in high risk and advanced MELanoma patients” (PRO-MEL) study is to assess HRQoL in high risk and advanced melanoma patients treated with immune checkpoint-inhibitors. Secondary outcomes are anxiety and depression; fear of cancer recurrence; melanoma-specific HRQoL; treatment-related symptoms; work ability; and information needs in high risk and advanced melanoma patients treated with immune checkpoint-inhibitors.

Who are working on this project?

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.